Kiora Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
San Diego, California--(Newsfile Corp. - November 12, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today reported financial results for the third quarter ended September 30, 2026, and provided a business update highlighted by the in-licensing of KIO-401, a late-stage, oral neuroprotective calpain inhibitor. The addition transforms Kiora's development pipeline, bringing in an asset supported by existing Phase 2 and Phase 3 studies conducted in Japan. Kiora is...